目的 探討復(fù)方柳菊膠囊聯(lián)合利福噴丁膠囊治療肺結(jié)核的臨床療效。方法 選取2019年3月—2020年9月在許昌市結(jié)核病防治所就診的92例肺結(jié)核患者，按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各有46例。對(duì)照組口服利福噴丁膠囊，0.6 g/次，2次/周。治療組在對(duì)照組基礎(chǔ)上口服復(fù)方柳菊膠囊，5粒/次，3次/d。兩組患者連續(xù)治療6個(gè)月。觀察兩組的臨床療效，比較兩組病灶吸收、空洞閉合、痰涂片轉(zhuǎn)陰的例數(shù)以及血清中白細(xì)胞介素-1β（IL-1β）、γ-干擾素（IFN-γ）、白細(xì)胞介素-8（IL-8）水平。結(jié)果 治療后，治療組患者的總有效率為95.65%，對(duì)照組的總有效率為82.61%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組患者病灶吸收、空洞閉合、痰涂片轉(zhuǎn)陰的例數(shù)比對(duì)照組高，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組IL-1β、IFN-γ、IL-8水平顯著降低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后治療組IL-1β、IFN-γ、IL-8水平低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 復(fù)方柳菊膠囊聯(lián)合利福噴丁膠囊治療肺結(jié)核療效顯著，能減輕臨床體征，降低炎癥反應(yīng)，且安全性良好。

Objective To investigate the clinical efficacy of Compound Liuju Capsules combined with Rifapentin Capsules in treatment of pulmonary tuberculosis. Methods Patients (92 cases) with pulmonary tuberculosis in Xuchang Tuberculosis Control Institute from March 2019 to September 2020 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Rifapentin Capsules, 0.6 g/time, twice weekly. Patients in the treatment group were po administered with Compound Liuju Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and the cases of focus absorption, cavity closure, and sputum smear negative, and the serum levels of IL-1β, IFN-γ, and IL-8 in two groups were compared. Results After treatment, the total effective rate was 95.65% in the treatment group, and 82.61% in the control group, and there was significant difference between the groups (P < 0.05). After treatment, the number of focal absorption, cavity closure, and sputum smear negative in the treatment group was higher than those in the control group (P < 0.05). After treatment, the levels of IL-1β, IFN-γ, and IL-8 in two groups were significantly decreased, and the difference was statistically significant (P < 0.05). After treatment, the levels of IL-1β, IFN-γ, and IL-8 in the treatment group were lower than those in the control group, and there was significant difference between two groups (P < 0.05). Conclusion Compound Liuju Capsules combined withRifapentin Capsules is effective in treatment of pulmonary tuberculosis, can reduce clinical signs and inflammatory reaction, with good safety.

R978.3